BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 24678744)

  • 1. Ocular findings in breast cancer patients using tamoxifen.
    Ugurlu S; Karagoz A; Altin Ekin M
    Cutan Ocul Toxicol; 2015 Mar; 34(1):16-20. PubMed ID: 24678744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multifocal electroretinography, color discrimination and ocular toxicity in tamoxifen use.
    Salomão SR; Watanabe SE; Berezovsky A; Motono M
    Curr Eye Res; 2007 Apr; 32(4):345-52. PubMed ID: 17453956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials.
    Gianni L; Panzini I; Li S; Gelber RD; Collins J; Holmberg SB; Crivellari D; Castiglione-Gertsch M; Goldhirsch A; Coates AS; Ravaioli A;
    Cancer; 2006 Feb; 106(3):505-13. PubMed ID: 16369994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The color appearance of stimuli detected via short-wavelength-sensitive cones for breast cancer survivors using tamoxifen.
    Eisner A; Incognito LJ
    Vision Res; 2006 May; 46(11):1816-22. PubMed ID: 16364390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crystalline maculopathy: a rare complication of tamoxifen therapy.
    Srikantia N; Mukesh S; Krishnaswamy M
    J Cancer Res Ther; 2010; 6(3):313-5. PubMed ID: 21119261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosage-dependent reduction of macular pigment optical density in female breast cancer patients receiving tamoxifen adjuvant therapy.
    Lim IL; Loo AVP; Subrayan V; Khang TF; See MH; Alip A; Taib NAM
    Breast; 2018 Jun; 39():117-122. PubMed ID: 29660599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocular toxicity in low-dose tamoxifen: a prospective study.
    Noureddin BN; Seoud M; Bashshur Z; Salem Z; Shamseddin A; Khalil A
    Eye (Lond); 1999 Dec; 13 ( Pt 6)():729-33. PubMed ID: 10707134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and in vivo confocal microscopy findings in patients receiving tamoxifen citrate.
    Muftuoglu O; Uçakhan OO; Kanpolat A
    Eye Contact Lens; 2006 Sep; 32(5):228-32. PubMed ID: 16974155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endometrial pathology at dilatation and curettage in breast cancer patients: comparison of tamoxifen users and nonusers.
    Gibson LE; Barakat RR; Venkatraman ES; Hoskins WJ
    Cancer J Sci Am; 1996; 2(1):35-8. PubMed ID: 9166496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The incidence of subsequent endometrial carcinoma with tamoxifen use in patients with primary breast carcinoma.
    Katase K; Sugiyama Y; Hasumi K; Yoshimoto M; Kasumi F
    Cancer; 1998 May; 82(9):1698-703. PubMed ID: 9576291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian cysts in tamoxifen-treated women with breast cancer.
    Inal MM; Incebiyik A; Sanci M; Yildirim Y; Polat M; Pilanci B; Nayki C; Camuzcuoğlu H
    Eur J Obstet Gynecol Reprod Biol; 2005 May; 120(1):104-6. PubMed ID: 15866095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eye problems in breast cancer patients treated with tamoxifen.
    Paganini-Hill A; Clark LJ
    Breast Cancer Res Treat; 2000 Mar; 60(2):167-72. PubMed ID: 10845279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The eyes have it! Tamoxifen maculopathy revisited: a case report.
    Nair AG; Das D; Goyal A; Gandhi RA
    J Ocul Pharmacol Ther; 2012 Dec; 28(6):640-2. PubMed ID: 22731242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
    Boccardo F; Rubagotti A; Puntoni M; Guglielmini P; Amoroso D; Fini A; Paladini G; Mesiti M; Romeo D; Rinaldini M; Scali S; Porpiglia M; Benedetto C; Restuccia N; Buzzi F; Franchi R; Massidda B; Distante V; Amadori D; Sismondi P
    J Clin Oncol; 2005 Aug; 23(22):5138-47. PubMed ID: 16009955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
    Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
    J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamoxifen and ocular toxicity.
    Ah-Song R; Sasco AJ
    Cancer Detect Prev; 1997; 21(6):522-31. PubMed ID: 9398992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short wavelength automated perimetry and tamoxifen use.
    Eisner A; Austin DF; Samples JR
    Br J Ophthalmol; 2004 Jan; 88(1):125-30. PubMed ID: 14693789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endometrial cancer after tamoxifen treatment: a descriptive study of 25 breast cancer patients who subsequently developed endometrial cancer.
    Peters-Engl C; Medl M; Danmayr E; Mirau M; Alth G; Leodolter S
    Anticancer Res; 1996; 16(5B):3241-6. PubMed ID: 8920798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen.
    Kimmick GG; Lovato J; McQuellon R; Robinson E; Muss HB
    Breast J; 2006; 12(2):114-22. PubMed ID: 16509835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of quantitative changes in hair growth during treatment with chemotherapy or tamoxifen in patients with breast cancer: a cohort study.
    Kanti V; Nuwayhid R; Lindner J; Hillmann K; Stroux A; Bangemann N; Kleine-Tebbe A; Blume-Peytavi U; Garcia Bartels N
    Br J Dermatol; 2014 Mar; 170(3):643-50. PubMed ID: 24641211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.